IMR Press / FBL / Volume 14 / Issue 1 / DOI: 10.2741/3244

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article
Superoxide, NO, peroxynitrite and PARP in circulatory shock and inflammation
Show Less
1 Department of Experimental Pharmacology, University of Naples “Federico II”, Via D. Montesano 49, Naples, Italy
2 IRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy
3 Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, Italy
Front. Biosci. (Landmark Ed) 2009, 14(1), 263–296; https://doi.org/10.2741/3244
Published: 1 January 2009
Abstract

Oxidative stress results from an oxidant/antioxidant imbalance, an excess of oxidants and/or a depletion of antioxidants. A vast amount of circumstantial evidence implicates oxygen-derived free radicals (especially, superoxide and hydroxyl radical) and high energy oxidants (such as peroxynitrite) as mediators of tissue injury associated with circulatory shock and inflammation. Reactive oxygen species (ROS) (e.g., superoxide, peroxynitrite, hydroxyl radical and hydrogen peroxide) are all potential reactants capable of initiating DNA single strand breakage, with subsequent activation of the nuclear enzyme poly (ADP ribose) synthetase (PARS), leading to eventual severe energy depletion of the cells, and necrotic-type cell death. Moreover, Poly (ADP-ribosyl)ation is regulated by the synthesizing enzyme poly (ADP-ribose) polymerase-1 (PARP-1) and the degrading enzyme poly (ADP-ribose) glycohydrolase (PARG). Here we review the roles of ROS, PARP-1 and PARG in circulatory shock and inflammation as well as the beneficial effect of the in vivo treatment with novel pharmacological tools (e.g. peroxynitrite decomposition catalysts, selective superoxide dismutase mimetics (SODm), PARP-1 and PARG inhibitors.

Share
Back to top